International Flavors & Fragrances Inc. reports developments across flavors, fragrances, food ingredients, health and biosciences for customers in food, beverage, personal care, home care, pet health and related markets. News frequently covers ingredient innovation, application labs and natural-extraction capabilities, including vanilla work in Madagascar and LMR Naturals in perfumery, cosmetics and flavors.
Company updates also address probiotics and bioscience products such as HOWARU Pet and PureStrong, nutrition claims tied to soy protein, quarterly earnings releases, dividends, and other capital or financial disclosures.
IFF (NYSE: IFF) launched CONCEPT MUSE, a proprietary artificial intelligence tool for generating food and beverage product concepts. The company says it helps teams move from inspiration to conceptualization in minutes rather than weeks, using consumer insights, market intelligence and flavor expertise. IFF experts frame prompts, evaluate outputs and refine results. The platform was demonstrated with customers at IFF’s FirsTaste event.
IFF (NYSE: IFF) reported third-quarter sales of $1.94 billion, up year over year, and raised its full-year guidance floors. Sales increased 4%, while continuing operations recorded a $134 million pretax loss and a diluted loss of $0.50 per share, versus earnings of $0.39 a year earlier. Adjusted operating EBITDA, a non-GAAP operating profit measure, was $403 million, up 5%, with a 20.8% margin.
IFF now expects 2026 sales of $7.5 billion–$7.6 billion and adjusted operating EBITDA of $1.55 billion–$1.60 billion. Nine-month operating cash flow, including discontinued operations, rose $288 million to $820 million. IFF completed its $500 million accelerated share repurchase program. The company expects softer fourth-quarter profitability and says the Food Ingredients divestiture remains on track to close by the end of the second quarter of 2027.
IFF (NYSE: IFF) announced that its Board of Directors declared a regular quarterly cash dividend of $0.40 per share. The dividend applies to the company's common stock and is payable on January 13, 2027, to shareholders of record as of December 19, 2026.
IFF (IFF) launched a consumer research report identifying ten food and beverage occasions linked to the changing needs of GLP-1 medication users. The report, “GLP-1 Consumer Moments of Opportunity,” offers manufacturers a framework for product development. IFF’s research describes needs ranging from protein-focused mornings and between-meal nourishment to planned treats and social eating.
A companion beverage framework identifies five hydration needs: Replenish, Maintain, Revitalize, Perform and Connect. Developed with InsightsNow, the research combines consumer research, snacking analysis, a review of more than 25,000 social media posts related to GLP-1 use and snacking, and secondary industry data.
IFF (NYSE: IFF) will release its third quarter 2026 earnings results after the market closes on November 3, 2026. Management will discuss results and outlook during a live webcast on November 4, 2026, at 9:00 a.m. ET. The webcast and accompanying slides will be available at ir.iff.com, with a recording available for replay.
IFF (NYSE: IFF) published Dear Dairy: The Life Stages Guide, a resource examining changing consumer priorities for dairy products throughout life. Drawing on Panoptic, its proprietary trend and foresight capability, the guide covers childhood, adolescence and young adulthood, adult routines, and healthy aging.
IFF identifies opportunities to align dairy products with each stage, from taste and nutrition for children to convenience for adults and nutrition supporting healthy aging. The guide includes four product concepts illustrating applications of its flavor, formulation and related technologies. It is intended for food and supplement producers, not final consumers.
IFF (NYSE: IFF) introduced AQUASCENT™, a vegan, water-based carrier for fine fragrance, as part of its Science of Performance platform.
IFF says the technology maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. The proprietary formula uses biodegradable materials and has no intentionally added ethanol, preservatives or silicone. It can be supplied as a concentrate, allowing brands to add water during final production rather than ship it within the formula.
IFF (IFF) launched Omni-Bos™ PHY, a novel phytase enzyme developed specifically for dairy cattle to improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed. The product will first be available in the Middle East, Africa and Asia-Pacific regions.
Omni-Bos™ PHY is designed to withstand ruminant digestive conditions and help cows better use protein, phosphorus and minerals in existing feed ingredients. In one study, it reduced undegraded phytate in the abomasum by approximately 70% compared with a control diet. Additional trials in lactating cows showed improved phosphorus and phytate digestibility, reduced nitrogen and phosphorus excretion, and increased digestibility of nutrients such as crude protein and calcium.
IFF (NYSE: IFF) released a new report, “Inside the India GLP-1 Consumer Journey,” analyzing how GLP-1 use is reshaping food behaviors among consumers in Delhi, Mumbai and Bengaluru. The study finds users are eating smaller portions while becoming more deliberate about nutrition, taste, ingredient quality and satisfaction.
Key data points include 74% reading food labels more carefully, 90% noticing changes in how food tastes or feels, 50% preferring softer textures, and 74% viewing hydration as a daily wellness goal, with many choosing coconut water and electrolyte-based beverages.
IFF (NYSE: IFF) announced that Chief Executive Officer Erik Fyrwald will take part in a fireside chat at the Barclays Global Consumer Conference/b) on . The discussion will be available via live webcast and subsequent replay on IFF’s investor relations website.